HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reoviridae Infections

Infections produced by reoviruses, general or unspecified.
Also Known As:
Infections, Reoviridae; Infection, Reoviridae; Infection, Reovirus; Infections, Reovirus; Reoviridae Infection; Reovirus Infection; Reovirus Infections
Networked: 208 relevant articles (7 outcomes, 14 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Persistent Infection
3. Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
4. Squamous Cell Carcinoma (Epidermoid Carcinoma)
5. Infections

Experts

1. Dermody, Terence S: 24 articles (01/2022 - 05/2003)
2. Tyler, Kenneth L: 15 articles (01/2019 - 03/2002)
3. Danthi, Pranav: 9 articles (01/2022 - 02/2006)
4. Clarke, Penny: 8 articles (01/2019 - 05/2003)
5. Tyler, K L: 8 articles (01/2005 - 04/2000)
6. Schiff, Leslie A: 7 articles (01/2018 - 08/2002)
7. Mainou, Bernardo A: 6 articles (01/2022 - 04/2008)
8. Clarke, P: 6 articles (01/2005 - 04/2000)
9. Holm, Geoffrey H: 5 articles (01/2018 - 02/2006)
10. Lee, Patrick W K: 5 articles (01/2012 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Reoviridae Infections:
1. AntibodiesIBA
2. Immunoglobulin G (IgG)IBA
3. VaccinesIBA
4. Proteins (Proteins, Gene)FDA Link
5. Immunoglobulins (Immunoglobulin)IBA
6. LigandsIBA
7. Niacin (Nicotinic Acid)FDA LinkGeneric
8. Folic Acid (Vitamin M)FDA LinkGeneric
9. Fish OilsIBA
10. Docosahexaenoic AcidsIBA

Therapies and Procedures

1. Therapeutics
03/15/2002 - "Reovirus infection in ex vivo primary human ovarian tumor surgical samples was also confirmed, further demonstrating the potential of reovirus therapy. "
04/01/2023 - "The TLRs (TLR1, 2, 3, 4, 7, 8) and RIG-1 distribution as determined by immunohistochemistry was examined in the following diseases: human papillomavirus (n = 30 including 15 squamous intraepithelial lesions (SIL), 5 cancers, and 10 controls); molluscum contagiosum (n = 8 including 4 controls), SARS-CoV2 (n = 52 including 20 mild, 5 fatal, and 27 controls) and reovirus infection as oncolytic therapy. "
10/01/2017 - "We identify sites of NKp46/NCR1 binding to sigma1 and show that sigma1 binding by NKp46/NCR1 leads to NK cell activation in vitro Finally, we demonstrate that NCR1 activation is essential for reovirus-based therapy in vivo Collectively, we have identified sigma1 as a novel ligand for NKp46/NCR1 and demonstrated that NKp46/NCR1 is needed both for clearance of reovirus infection and for reovirus-based tumor therapy.IMPORTANCE Reovirus infects much of the population during childhood, causing mild disease, and hence is considered to be efficiently controlled by the immune system. "
10/01/2017 - "Using several mouse tumor models, we demonstrate the importance of NK cells in protection from reovirus infection and in reovirus killing of tumors in vivo Collectively, we identify a new ligand for the NKp46 receptor and provide evidence for the importance of NKp46 in the control of reovirus infections and in reovirus-based cancer therapy."
05/01/2013 - "In vitro analyses confirmed colocalisation of markers of reovirus infection and caspase 3. Triple therapy was significantly more effective than reovirus or cisplatin-paclitaxel in athymic nude mice. "